Momeclir

Symptomatic treatment of seasonal allergic or perennial rhinitis in adults & childn ≥2 yr. Prophylactic treatment initiated up to 4 wk prior to the anticipated start of pollen season in patients who have history of moderate to severe symptoms of seasonal allergic rhinitis. Treatment of nasal polyps in adults ≥18 yr; acute rhinosinusitis w/o severe bacterial infection in adults & childn ≥12 yr.

Seasonal or perennial allergic rhinitis Adult (including geriatric patient) & childn ≥12 yr 2 actuations (50 mcg/actuation) in each nostril once daily (total dose: 200 mcg). May be increased to max daily dose of 4 actuations in each nostril once daily (total dose: 400 mcg) if symptoms are inadequately controlled. Maintenance: Reduce dose to 1 actuation in each nostril (total dose: 100 mcg) once symptoms are controlled. Childn 6-11 yr 1 actuation (50 mcg/actuation) in each nostril once daily (total dose: 100 mcg). Nasal polyposis Initially, 2 actuations (50 mcg/actuation) in each nostril once daily (total daily dose: 200 mcg), may be increased to a daily dose of 2 sprays in each nostril bid (total daily dose: 400 mcg) if symptoms are inadequately controlled after 5-6 wk. Titrate dose to lowest dose at which effective control of symptoms is maintained. Acute rhinosinusitis Initially, 2 actuations (50 mcg/actuation) in each nostril bid (total dose: 400 mcg).

Hypersensitivity. Not to be used in the presence of untreated localized infection involving nasal mucosa; in patients who have experienced recent nasal surgery or trauma until healing has occurred.

Discontinue therapy if localized fungal infection of the nose or pharynx develops. Patients w/ active or quiescent tuberculous infections of the resp tract, or untreated fungal, bacterial, or systemic viral infections; patients transferred from long-term administration of systemically active corticosteroids to nasal spray susp. Patients using mometasone furoate over several mth or longer should be examined periodically for possible changes in nasal mucosa. During transfer from systemic corticosteroids, some patients may experience symptoms of w/drawal from systemically active corticosteroids (eg, joint &/or muscular pain, lassitude, & depression initially) despite relief from nasal symptoms & may also unmask pre-existing allergic conditions, eg, allergic conjunctivitis & eczema, previously suppressed by systemic corticosteroid therapy. Safety & efficacy has not been studied for use in the treatment of unilateral polyps, polyps associated w/ cystic fibrosis or polyps that completely obstruct the nasal cavities. Risk of exposure to certain infections (eg, chickenpox, measles) in patients receiving corticosteroids who are potentially immunosuppressed. Very rare reports of nasal septum perforation or increased IOP following use of intranasal corticosteroids. May result in clinically significant adrenal suppression if treated w/ higher than recommended doses. Pregnancy & lactation. Infants born of mothers who received corticosteroids during pregnancy should be observed carefully for hypoadrenalism. Regularly monitor height of childn receiving prolonged treatment w/ nasal corticosteroids at licensed doses as growth retardation may occur.

Epistaxis. Allergic rhinitis in adult & adolescent patients: Headache; pharyngitis, nasal burning, irritation, & ulceration. Polyposis: URTI; throat irritation; headache.

Nasal Decongestants & Other Nasal Preparations

D07AC13 - mometasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.

Rx